3360-79-0

Basic information

• Product Name: 4-METHOXY-N-METHYL-2-NITROBENZENAMINE
• Synonyms: 4-METHOXY-N-METHYL-2-NITROANILINE;4-METHOXY-N-METHYL-2-NITROBENZAMINE;4-METHOXY-N-METHYL-2-NITROBENZENAMINE;4-Methoxy-N-methyl-2-nitrobenzenamine95%;4-METHOXY-N-METHYL-2-NITROBENZENAMINE 95%
• CAS NO: 3360-79-0
• Molecular Formula: C₈H₁₀N₂O₃
• Molecular Weight: 182.18
• Mol File: 3360-79-0.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 333.1 °C at 760 mmHg
• Flash Point: 155.3 °C
• Appearance: /
• Density: 1.258 g/cm³
• Vapor Pressure: 0.000139mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-METHOXY-N-METHYL-2-NITROBENZENAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXY-N-METHYL-2-NITROBENZENAMINE(3360-79-0)
• EPA Substance Registry System: 4-METHOXY-N-METHYL-2-NITROBENZENAMINE(3360-79-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 3360-79-0(Hazardous Substances Data)

Usage

General Description

4-Methoxy-N-methyl-2-nitrobenzenamine is a chemical substance with a molecular formula of C8H10N2O3. It belongs to the category of organic compounds known as nitroanilines, which are compounds containing aniline (an organic compound with the formula C6H5NH2) and a nitro group. This particular compound features nitro and amine functional groups attached to a benzene ring, indicating its potential as a precursor in synthesizing more complex chemical structures. As with other similar compounds, its potential health effects, toxicity, and safety handling measures are essential considerations in its use, particularly within an industrial or laboratory context. Its exact applications can vary across different scientific fields.

InChI:InChI=1/C8H10N2O3/c1-9-7-4-3-6(13-2)5-8(7)10(11)12/h3-5,9H,1-2H3

Upstream product

• 77-78-1 dimethyl sulfate 
• 96-96-8 4-methoxy-2-nitroaniline 
• 74-89-5 methylamine 
• 61324-93-4 1-fluoro-nitro-4-methoxybenzene 
• 3360-81-4 N-(4-methoxy-2-nitrophenyl)-4-methylbenzenesulfonamide 
• 1150-26-1 N-(4-Methoxy-phenyl)-4-methyl-benzenesulfonamide 
• 51-66-1 4-methoxyacetanilide 
• 119-81-3 4-methoxy-2-nitroacetanilide 
• 67-56-1 methanol 
• 74-88-4 methyl iodide 
• 22809-78-5 N-(4-methoxyphenyl)-N-methylnitramine 
• 128691-93-0 4-methoxy-2-nitrotrifluoroacetanilide 
• 85122-54-9 3-nitro-4(benzotriazol-1-ylmethyl)aminoanisole 
• 85020-96-8 acetic acid-(4-methoxy-N-methyl-2-nitro-anilide) 

Downstream Products

• 10394-39-5 5-methoxy-1-methyl-1H-benzo[d]imidazole 
• 3360-78-9 4-methoxy-N-methyl-1,2-phenylenediamine 
• 344767-35-7 Naphthalene-1,7-dicarboxylic acid bis-[(4-methoxy-2-nitro-phenyl)-methyl-amide] 
• 68426-83-5 (5-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)methanol 
• 50591-22-5 1-methyl-1H-benzo[d]imidazol-5-ol 
• 1450610-34-0 C₁₁H₁₃N₃O₄ 
• 1190761-82-0 3-(2-((4-methoxy-2-nitrophenyl)(methyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 
• 1450610-30-6 C₁₁H₁₆N₄O₄ 
• 1450610-28-2 C₁₂H₁₆N₂O₅ 
• 36242-33-8 N-methyl N-carboethoxy acetyl 2-nitro 4-methoxy aniline 
• 80776-49-4 1-Methyl-6-methoxy-1,4-dihydroquinoxalin-2,3-dione 
• 61154-62-9 [(4-methoxy-2-nitro-phenyl)-methyl-sulfamoyl]-acetic acid 
• 61154-89-0 7-methoxy-1-methyl-2,2-dioxo-5-phenyl-1,2,3,5-tetrahydro-2λ⁶-benzo[c][1,2,5]thiadiazepin-4-one 
• 1805-02-3 5-methoxy-1-methyl-1H-benzoimidazol-2-ylamine 

Relevant articles and documents

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

Development of a Selective Inhibitor of Protein Arginine Deiminase 2

Protein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer. To date, no PAD2-selective inhibitor has been developed. Such a compound will be critical for elucidating the